GlassScriptPhysician profile
Sanjay Yadav
NPI 1528177714
$702.75
in general payments reported to CMS, 2019-2025
14 companies · $17.22 in 2025
The $17.22 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $79.69 · 2021: $110 · 2022: $32.90 · 2023: $146 · 2024: $146 · 2025: $17.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $309.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $201.60 | 2023-2024 | Jaypirca |
| Merck Sharp & Dohme LLC | $124.83 | 2019 | |
| Eisai INC. | $73.18 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $52.54 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $39.10 | 2021-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $32.94 | 2020-2021 | |
| Seagen INC. | $32.90 | 2022 | |
| Pfizer INC. | $30.65 | 2019 | |
| Amag Pharmaceuticals, INC. | $30.20 | 2019-2020 | |
| Celgene Corporation | $24.26 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.13 | 2023 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Yadav listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.